Desidustat Drug Asset Due Diligence Report 2026

This Desidustat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Desidustat can convert its Small molecule drug profile and HIF-PHs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Desidustat (query alias: desidustat)
Modality / target	Small molecule drug; HIF-PHs; HIF-PHs inhibitors
Highest global status	Approved
Originator	Zydus Cadila Healthcare Ltd.
Active developers	Zydus Lifesciences Ltd., Yiqiao Hunan Pharmaceuticals Co. Ltd.

The MCP disease footprint includes Anemia in chronic kidney disease, chronic renal failure anemia, Anemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTRI/2024/08/072443	Phase 4	Not Yet Recruiting	80	Not disclosed
CTRI/2025/08/092897	Phase 3	Open to Recruitment	156	Not disclosed
CTRI/2025/08/093855	Not Applicable	Not Yet Recruiting	40	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

#3932 Desidustat in chronic kidney disease anaemia: real-world experience and outcomes

Not Applicable; n=99; evaluation: Positive. Reported fields: Hb(increase; 6 months) = 1.63 g/dL

#2639 A retrospective, multicenter study on the efficacy and safety of desidustat in chronic kidney disease-induced anemia

Not Applicable; n=535; evaluation: Positive. Reported fields: Hemoglobin level(follow-up 1) = 9.83 g/dL ( 1.52)

Real-World Experience of Hypoxia-Inducing Factor-Prolyl Hydroxylase Inhibitor Desidustat for Anemia in Dialysis-Dependent CKD

Not Applicable; n=65; evaluation: Positive. Reported fields: AE = There were no major adverse events during the follow-up duration.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Desidustat addresses Anemia in chronic kidney disease, chronic renal failure anemia, Anemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-10-30	Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat,a critical treatment option for Chronic Kidney Disease patients in India	Approved	Financial terms not disclosed
2020-01-20	Zydus enters into licensing agreement with China Medical System Holdings	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “A green process for the preparation of crystalline desidustat”. The milestone feed surfaced a patent-application signal described as “Desidustat particles and compositions thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO